Antibiotic treatment of osteomyelitis: what have we learned from 30 years of clinical trials?

被引:208
|
作者
Lazzarini, L [1 ]
Lipsky, BA
Mader, JT
机构
[1] S Bortolo Hosp, Dept Infect Dis & Trop Med, I-36100 Vicenza, Italy
[2] VA Puget Sound Hlth Care Syst, Med Serv, Seattle, WA USA
[3] VA Puget Sound Hlth Care Syst, Antibiot Res Clin, Seattle, WA USA
[4] Univ Washington, Dept Med, Seattle, WA USA
[5] Univ Texas, Med Branch, Galveston, TX USA
关键词
osteomyelitis; infection; bone; antibiotic; therapy; treatment;
D O I
10.1016/j.ijid.2004.09.009
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives and design: To determine the most appropriate approach to antibiotic therapy for osteomyelitis, the medical literature for articles published from 1968 to 2000 was reviewed. Results: Ninety-three clinical trials in children and adults were identified using almost every antibiotic class. Most studies were non-comparative and the comparative trials involved relatively few patients. Publications generally did not provide clinically important information regarding infection staging or classification, surgical treatment provided, or the presence of orthopedic hardware. The median duration of follow-up after treatment was only 12 months. The clinical outcome was better for acute than chronic osteomyelitis in eight of the 12 studies allowing comparison. In the comparative trials, few statistically significant differences were observed between the tested treatments. In one small trial, the combination of nafcillin plus rifampin was more effective than nafcillin alone. In pediatric osteomyelitis, oral therapy with cloxacillin was more effective than tetracycline in one study, and oral clindamycin was as effective as parenteral. antistaphylococcal penicillins in another. In several investigations oral. fluoroquinolones were as effective as standard parenteral treatments. Conclusions: Although the optimal duration of antibiotic therapy remains undefined, most investigators treated patients for about six weeks. Despite three decades of research, the available Literature on the treatment of osteomyelitis is inadequate to determine the best agent(s), route, or duration of antibiotic therapy. (c) 2005 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:127 / 138
页数:12
相关论文
共 50 条
  • [41] Governance by numbers: what have we learned over the past 30 years?
    Jackson, Peter M.
    PUBLIC MONEY & MANAGEMENT, 2011, 31 (01) : 13 - 26
  • [42] Diabetic foot infections: what have we learned in the last 30 years?
    Uckay, Ilker
    Aragon-Sanchez, Javier
    Lew, Daniel
    Lipsky, Benjamin A.
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2015, 40 : 81 - 91
  • [43] Stem cells in the management of heart failure: what have we learned from clinical trials?
    Vogel, Rebecca
    Hussein, Emad A.
    Mousa, Shaker A.
    EXPERT REVIEW OF CARDIOVASCULAR THERAPY, 2015, 13 (01) : 75 - 83
  • [44] Strategies to overcome accelerated repopulation and hypoxia - What have we learned from clinical trials?
    Corry, J
    Rischin, D
    SEMINARS IN ONCOLOGY, 2004, 31 (06) : 802 - 808
  • [45] Twin-twin transfusion syndrome - What we have learned from clinical trials
    Djaafri, Fatiha
    Stirnemann, Julien
    Mediouni, Imen
    Colmant, Claire
    Ville, Yves
    SEMINARS IN FETAL & NEONATAL MEDICINE, 2017, 22 (06): : 367 - 375
  • [46] Introducing what have we learned about PD from recent major clinical trials?
    Blake, Peter G.
    PERITONEAL DIALYSIS INTERNATIONAL, 2007, 27 (01): : 10 - 10
  • [47] THROMBOLYTICS, ADJUVANT THERAPIES IN MI - WHAT HAVE WE LEARNED FROM THE CLINICAL-TRIALS
    AMIDON, TM
    FIGUEREDO, V
    WOLFE, CL
    HOSPITAL FORMULARY, 1993, 28 (06): : 558 - &
  • [48] What have we learned from observational studies and clinical trials of mild to moderate COPD?
    Miriam Barrecheguren
    Cruz González
    Marc Miravitlles
    Respiratory Research, 19
  • [49] What have we learned from observational studies and clinical trials of mild to moderate COPD?
    Barrecheguren, Miriam
    Gonzalez, Cruz
    Miravitlles, Marc
    RESPIRATORY RESEARCH, 2018, 19
  • [50] 30 years of repeat expansion disorders: What have we learned and what are the remaining challenges?
    Depienne, Christel
    Mandel, Jean-Louis
    AMERICAN JOURNAL OF HUMAN GENETICS, 2021, 108 (05) : 764 - 785